FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280493737> ?p ?o ?g. }

• W4280493737 endingPage "e004533" @default.
• W4280493737 startingPage "e004533" @default.
• W4280493737 abstract "Background Activin-A, a transforming growth factor β family member, is secreted by many cancer types and is often associated with poor disease prognosis. Previous studies have shown that Activin-A expression can promote cancer progression and reduce the intratumoral frequency of cytotoxic T cells. However, the underlying mechanisms and the significance of Activin-A expression for cancer therapies are unclear. Methods We analyzed the expression of the Activin-A encoding gene INHBA in melanoma patients and the influence of its gain- or loss-of-function on the immune infiltration and growth of BRAF -driven YUMM3.3 and iBIP2 mouse melanoma grafts and in B16 models. Using antibody depletion strategies, we investigated the dependence of Activin-A tumor-promoting effect on different immune cells. Immune-regulatory effects of Activin-A were further characterized in vitro and by an adoptive transfer of T cells. Finally, we assessed INHBA expression in melanoma patients who received immune checkpoint therapy and tested whether it impairs the response in preclinical models. Results We show that Activin-A secretion by melanoma cells inhibits adaptive antitumor immunity irrespective of BRAF status by inhibiting CD8 + T cell infiltration indirectly and even independently of CD4 T cells, at least in part by attenuating the production of CXCL9/10 by myeloid cells. In addition, we show that Activin-A/ INHBA expression correlates with anti-PD1 therapy resistance in melanoma patients and impairs the response to dual anti-cytotoxic T-Lymphocyte associated protein 4/anti-PD1 treatment in preclinical models. Conclusions Our findings suggest that strategies interfering with Activin-A induced immune-regulation offer new therapeutic opportunities to overcome CD8 T cell exclusion and immunotherapy resistance." @default.
• W4280493737 created "2022-05-22" @default.
• W4280493737 creator A5008398236 @default.
• W4280493737 creator A5063672693 @default.
• W4280493737 creator A5064346931 @default.
• W4280493737 creator A5068392630 @default.
• W4280493737 creator A5078536746 @default.
• W4280493737 creator A5078625040 @default.
• W4280493737 creator A5088445120 @default.
• W4280493737 date "2022-05-01" @default.
• W4280493737 modified "2023-10-15" @default.
• W4280493737 title "Activin-A impairs CD8 T cell-mediated immunity and immune checkpoint therapy response in melanoma" @default.
• W4280493737 cites W1019458012 @default.
• W4280493737 cites W1850152419 @default.
• W4280493737 cites W1967490534 @default.
• W4280493737 cites W1976928968 @default.
• W4280493737 cites W1977151351 @default.
• W4280493737 cites W1982871919 @default.
• W4280493737 cites W1991046191 @default.
• W4280493737 cites W2004298917 @default.
• W4280493737 cites W2019400355 @default.
• W4280493737 cites W2045387875 @default.
• W4280493737 cites W2054869131 @default.
• W4280493737 cites W2058160830 @default.
• W4280493737 cites W2061778966 @default.
• W4280493737 cites W2068625824 @default.
• W4280493737 cites W2076862329 @default.
• W4280493737 cites W2098984609 @default.
• W4280493737 cites W2099560139 @default.
• W4280493737 cites W2108218187 @default.
• W4280493737 cites W2112740421 @default.
• W4280493737 cites W2126977518 @default.
• W4280493737 cites W2158869405 @default.
• W4280493737 cites W2162222767 @default.
• W4280493737 cites W2223204800 @default.
• W4280493737 cites W2299181842 @default.
• W4280493737 cites W2417761579 @default.
• W4280493737 cites W2464900585 @default.
• W4280493737 cites W2560186680 @default.
• W4280493737 cites W2612805962 @default.
• W4280493737 cites W2614958352 @default.
• W4280493737 cites W2621162770 @default.
• W4280493737 cites W2621233176 @default.
• W4280493737 cites W2753432434 @default.
• W4280493737 cites W2791467603 @default.
• W4280493737 cites W2797752921 @default.
• W4280493737 cites W2808009807 @default.
• W4280493737 cites W2883378690 @default.
• W4280493737 cites W2891241542 @default.
• W4280493737 cites W2903719632 @default.
• W4280493737 cites W2936414047 @default.
• W4280493737 cites W2959016616 @default.
• W4280493737 cites W2965413325 @default.
• W4280493737 cites W2971099963 @default.
• W4280493737 cites W2975736787 @default.
• W4280493737 cites W2981830193 @default.
• W4280493737 cites W2982017357 @default.
• W4280493737 cites W2984792249 @default.
• W4280493737 cites W3043703771 @default.
• W4280493737 cites W3045128685 @default.
• W4280493737 cites W3085427829 @default.
• W4280493737 cites W3095751456 @default.
• W4280493737 cites W3106021040 @default.
• W4280493737 cites W3109702162 @default.
• W4280493737 cites W3133489395 @default.
• W4280493737 doi "https://doi.org/10.1136/jitc-2022-004533" @default.
• W4280493737 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35580932" @default.
• W4280493737 hasPublicationYear "2022" @default.
• W4280493737 type Work @default.
• W4280493737 citedByCount "4" @default.
• W4280493737 countsByYear W42804937372022 @default.
• W4280493737 countsByYear W42804937372023 @default.
• W4280493737 crossrefType "journal-article" @default.
• W4280493737 hasAuthorship W4280493737A5008398236 @default.
• W4280493737 hasAuthorship W4280493737A5063672693 @default.
• W4280493737 hasAuthorship W4280493737A5064346931 @default.
• W4280493737 hasAuthorship W4280493737A5068392630 @default.
• W4280493737 hasAuthorship W4280493737A5078536746 @default.
• W4280493737 hasAuthorship W4280493737A5078625040 @default.
• W4280493737 hasAuthorship W4280493737A5088445120 @default.
• W4280493737 hasBestOaLocation W42804937371 @default.
• W4280493737 hasConcept C154317977 @default.
• W4280493737 hasConcept C167672396 @default.
• W4280493737 hasConcept C193419808 @default.
• W4280493737 hasConcept C202751555 @default.
• W4280493737 hasConcept C203014093 @default.
• W4280493737 hasConcept C2776090121 @default.
• W4280493737 hasConcept C2776107976 @default.
• W4280493737 hasConcept C2777658100 @default.
• W4280493737 hasConcept C2777701055 @default.
• W4280493737 hasConcept C2780851360 @default.
• W4280493737 hasConcept C502942594 @default.
• W4280493737 hasConcept C55493867 @default.
• W4280493737 hasConcept C71924100 @default.
• W4280493737 hasConcept C86803240 @default.
• W4280493737 hasConcept C8891405 @default.
• W4280493737 hasConcept C90375314 @default.
• W4280493737 hasConceptScore W4280493737C154317977 @default.

• next